Available online on 15.02.2025 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access  Full Text Article                                                                                                                                                                 Review Article

Nanotechnology in Drug Delivery System: A New Approach

Sanket Pandurang Shinde ¹*, Christopher Benjamin Lobo ², Harshal Suresh Singh Rajput ², Gaurav Fulchand Nikam ²

¹ Assistant Professor, Department of Quality Assurance Techniques, Dr. Babasaheb Ambedkar Technological University, Pune, Maharashtra, India-412216.

² Research Scholar, Department of Pharmaceutics, Dr. Babasaheb Ambedkar Technological University, Pune, Maharashtra, India-412216.

Introduction

Nanoscience is the only platform to discover the new properties of matter by collaborating with conventional fields such as applied health, molecular chemistry, molecular science, pharmaceutical science, optics, and even engineering. In recent decades, science and technology have frequently been well-architected to address the challenges in the medical and health sciences by offering therapeutic approaches, nano-medical equipment, and a more efficient health system. In the past, Professor N. Taniguchi was the first to use the word "nanotechnology" in 1974. Drexler quickly created and published the first nanotechnology concept (Feynman's concepts) in his 1986 book "Vehicles of Creation: The Coming of the Nanotechnology Era"¹.

The effects of nanotechnology on humans and animals are currently opening up new research directions and transforming health science, making it a crucial topic for therapeutic tool consideration. By developing new devices and characterizing material structure technologies with special properties, nanotechnology, a very shady multidisciplinary field, was created to engineer biological matters like atoms, molecules, and supramolecules at the nanoscale range of about 1 to 100 nm. This holds promise against current challenges by studying and comprehending deadly biological problems, followed by the diagnosis and treatment of disease^2,3. The most prevalent and widely used technology of the past few decades is nanotechnology, which is also extremely important to human life. Notably, the components of living cells are incredibly important pieces of equipment that are minuscule (nanoscale). They have a strong role in practically every biological process, such as metabolism, energy production, cell signalling, and nutrient transport. In order to address biology and medicine for therapeutic objectives, nanotechnology might be considered a crucial candidate that can provide new technologies at the individual matter level⁴. The development of numerous nanoscale materials with numerous therapeutic benefits has led to the rise of nano-medicine as the gold standard in the health sciences^5,6.There are many benefits of generating and distributing various nanomedicine products through the pathophysiological and clinically linked regulation of diseased/abnormal tissues/cells. Therefore, there may be a variety of strategies to improve the prognosis of the disease using tissue-specific medication targeting techniques⁷. In the varied field of medical science, nanomaterials more specifically, metal nanoparticles have drawn more attention in recent years. Nowadays, a lot of research is being done on how to best synthesize nanomaterials such polymers, micelles, dendrimers, liposomes, emulsions, nanocapsules, and nanoparticles. One of the most prominent uses of nanotechnology today is nanomedicine, which is dedicated to creating nanoscale medical instruments to support an efficient healthcare system. This method enables us to better understand human physiology in order to combat a number of fatal illnesses, including cancer and cardiovascular ailments. In order to precisely deliver drugs to target sites and improve treatment outcomes by lowering toxicities and off-target effects, nanomedicine is primarily used for imaging, disease diagnosis, tissue engineering, and designing more effective, affordable, and safe drug delivery systems⁸.The use of nanoscale instruments and materials to identify, treat, and prevent illnesses is known as nanotechnology in medicine. This approach frequently makes tailored medication delivery and sophisticated diagnostic imaging possible. For instance, in medicine, any size smaller than a micrometer is referred to as nanometric; this dimension can be used to regulate the body's drug distribution or the interactions between implants and tissue⁹.

History of Nanotechnology

One of the most important technologies of the twenty-first century is nanotechnology. It goes without saying that the creation and application of the smallest particles that are invisible to the human eye are not modern innovations. The famed Damascene Swords, several late medieval church windows, and the Lycurgus Cup from the fourth century AD on display at the British Museum in London are a few examples of the earlier employment of nanomaterials. The ancient Roman cup appears olive green when illuminated from the outside but turns purple when illuminated from the inside, revealing a legendary ruler. This phenomenon is caused by colloidal nanoparticles of gold and silver that are present in the glass. Some late medieval church windows have a similar effect, shining a dazzling red and yellow due to the fusion of gold and silver nanoparticles into the glass. A 17th-century Damascene blade was found to contain nanometer-sized carbon particles in 2006; these particles are what give the fabled swords their flexibility and resilience¹⁰. In 1902, Richard Zsigmondy and Henry Siedentopf's ultramicroscope was used to successfully discern features in ruby glasses that were smaller than 4 nanometers¹¹. Zsigmondy submitted a patent application for the immersion ultramicroscope in 1912, which made it feasible to study the behaviour of colloidal solutions. The transmission electron microscope (TEM), created by Max Knoll and Ernst Ruska, began to reach noticeably higher resolutions in 1931 than the light microscopes that had been in use until that time¹². In his 1959 paper ‘There is Plenty of Room at the Bottom’, physicist and Nobel laureate Richard P. Feynman foresaw the emergence of nanotechnologies and the opportunities that would come with them. A call to explore a new area of physics. Furthermore, this paper is considered the foundational text of nanotechnology, despite the fact that the word "nano" does not appear once in it. In addition to predicting that the development of more accurate microscopes will allow access to the field of individual atoms and that it would be possible to arrange atoms as desired, Feynman challenged us to think about the creation and control of microscopic devices based on quantum mechanics¹³. In the first and most contentious book on nanotechnology, “The Coming Era of Nanotechnology”, author K. Eric Drexler explained how to build complex machines out of individual atoms that can independently manipulate molecules and atoms to produce things and replicate themselves¹⁴. In their book Unbounding the Future, K. Eric Drexler, Chris Peterson, and Gayle Pergamit outline the potential use of such "nanobots" or "assemblers" in the medical field. The phrase "nanomedicine" was allegedly first used in ‘The Nanotechnology Revolution’, which was published in 1991¹⁵. With the publication of Robert A. Freitas' book Nanomedicine in 1999, the term gained popularity and has been used in technical writing ever since. Since Feynman and Drexler's vision of nanoscale robots that patrol the body, neutralize disease foci, and identify and repair organs and cells with impaired function is still a way off, nanomedicine focuses on investigating the potential for controlling and modifying cell processes, such as by delivering active substances to specific locations¹⁶.

Paul Ehrlich made an effort at the start of the 20th century to create ‘magic bullets’ that could be used to target diseases and eradicate all germs with just one treatment. He created Salvarsan, which is considered to be the first precisely acting medication of this kind and the precursor to chemotherapy. Production of increasingly complex ‘magic bullets’ was made possible by the 20th century's discoveries about cells and their components, intracellular and intercellular activities, and cell communication, as well as developments in biochemistry and biotechnology¹⁷. Currently, biocompatible polymers, liposomes, and micelles are being studied as medication, vaccine, and gene carriers. Nanomaterials can circulate within the body until they reach their target because of their small size (often less than 200 nm), which prevents them from being filtered out of the blood¹⁸.

Advantages of Nanotechnology:

1. Targeted Drug Delivery: Active targeting is when the drug carrier system is conjugated to a tissue or cell-specific ligand, while passive targeting is when nanoparticle reaches the target organ due to the leaky junctions¹⁹.
2. Improved bioavailability by enhancing aqueous solubility²⁰.
3. Increasing resistance time in the body (increasing half-life for clearance/increasing specificity for its cognate receptors)²¹.
4. Improved therapeutic effects and drug solubility improved therapeutic effects and drug solubility²².

Disadvantages of Nanotechnology:

1. Toxicity: Nanoparticles can have unexpected toxic effects on cells, including damage to DNA, proteins, and lipids²³.
2. Drug resistance: Nanoparticles can help deliver chemotherapy drugs to tumors, but tumor cells can develop resistance to these drugs over time²⁴.
3. Oxidative stress: Inhaled nanoparticles can cause oxidative stress²⁵.
4. Inflammation: Inhaled nanoparticles can cause inflammation in the lungs²⁶.

FIGURE.1: The composition of polymer nanocarrier platforms with their drug-loading methods²⁷

Polymeric Nanocarriers:

1. Solid polymeric nanoparticles

The therapeutic drug is dissolved, entrapped, encapsulated, or adsorbed into the constituent polymer matrix of solid polymeric nanoparticles (NPs), which are solid colloidal systems²⁸.For focused medication delivery, several solid polymeric nanoparticles have been created. As an illustration, consider the PEGylated poly(lactic-co-glycolic acid) (PEG–PLGA) NP loaded with paclitaxel (PTX), which produced a better lethal effect on liver tumour growth both in vitro and in vivo as compared to the free drug²⁹.

2. Polymeric micelle nanoparticles

Polymeric micelle nanoparticles have a hydrophobic core and a spherical, amphiphilic, self-assembling core or shell shape that facilitates drug encapsulation. Polymeric micelles have demonstrated remarkable drug-carrying capacity in oncotherapy³⁰. Research by Jin et al. to determine the impact of PTX-loaded N-octyl-O-sulphate chitosan micelles on the treatment of multidrug-resistant malignancy serves as one example. The micelles show strong in vivo tumour inhibition and a two fold increase in cellular absorption compared to the free medicines³¹.

3. Polymeric dendrimers

The dendrimers are artificial macromolecules that have several extensions extending from the central core, giving them a tree-like structure. Either the dendrimer surface or the core can contain conjugated or encapsulated therapeutic substances³². The poly (glycol-succinic acid) dendrimers that carry camptothecin are one instance. When treating human breast cancer (MCF-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblastoma (SF-268), increased drug absorption and cytotoxicity up to 16 and 7-fold, respectively, were reported in comparison with the free drug³³.

4. Polymersomes

Synthetic copolymers known as polymersomes self-assemble into distinct hydrophobic and hydrophilic blocks. Polymersomes are more stable, have greater storage capacity, and have a longer circulation time than liposomal NPs, despite this. Polymersome vesicles containing DOX were found to be more effective at suppressing tumour growth in comparison to liposomal NPs³⁴.

5. Polyplexes

Polyplexes are polymer nanocarriers. Through electrostatic interactions, genes or siRNA are bonded to the cationic polymer group in polyplexes. The primary application of polyplexes is in cancer-specific gene therapy. The polymeric vectors based on galactose-modified trimethyl chitosan-cysteine are one example. When evaluated in human lung cancer (A549) and liver cancer (QGY-7703) cells, these polyplexes demonstrated excellent in vitro and in vivo capability of delivering siRNA, leading to effective and long-lasting gene suppression³⁵.

6. Polymer-lipid hybrid

The polymer-lipid hybrid system, which combines liposomes with polymeric NPs. This system consists of a hydrophilic shell with a hydrophobic core, separated by a lipidic monolayer. Wong et al. investigated a system in which a polymer derived from soybean oil was conjugated to DOX and then dispersed with lipid in water. DOX was delivered well, and P-gp-overexpressing human breast cancer cell lines had eight times more cytotoxicity³⁶.

The therapeutic drug was either encapsulated inside the polymeric core of each of these polymeric nanocarrier types or adhered to the NP surface³⁷.

Ideal characteristics

To optimize its effectiveness and safety, the perfect nanoscale medication delivery system would have a number of essential characteristics. Among them are:

1. Targeted delivery is the capacity to distribute medications just to the targeted cells or tissues, limiting side effects and minimizing off-target effects³⁸.
2. Controlled Release: The capacity to gradually and deliberately release the medication over time, maintaining a therapeutic impact and minimizing the need for repeated dosage³⁹.
3. Biocompatibility: Materials ought to be in harmony with the body and not cause toxicity or an immunological reaction⁴⁰.
4. Stability: To guarantee that the medication is effective until it reaches its target, the system must be stable in both biological environments and storage⁴¹.
5. The ideal size, usually in the nanoscale range, and surface features to enable cellular absorption and passage through biological barriers, such as the blood-brain barrier⁴².
6. Biodegradability: To avoid building up in tissues, nanoparticles should be able to break down metabolically. Lipids, proteins, and polymers are among the materials frequently employed for this purpose⁴³.
7. Improved solubility and absorption of medications, especially those with low solubility or low bioavailability when taken orally, is known as enhanced bioavailability⁴⁴.
8. Scalability and reproducibility: Easy production at a scale that meets clinical and commercial requirements, as well as consistent quality across batches⁴⁵.

Table 1: Types of nanotechnology^46-48

DRUG SELECTION CRITERIA

The five principles for the manufacture of safe nanoparticles serve as the basis for selecting the major and sub-criteria connected to the preparation of calprotectin-loaded polymeric nanoparticles, as well as possible alternatives.

 To be more precise, the guiding ideas are as follows:

• Cutting a medicine down to a nanoscale level without affecting how it works.
• Substituting appropriate nontoxic chemicals for the hazardous ones utilized in the preparation.
• Atoms and molecules bonding to nanoparticles without causing toxicity while maintaining the product's intended feature.
• Encasing highly toxic pharmaceuticals in harmless polymers to lower the drug's toxicity.
• When it is not possible to avoid using harmful chemicals, use them in small quantities. There were eight viable approaches or substitutes chosen to create polymeric nanoparticles^49,50.

EXCIPIENTS^51-61

NADDSs provide particular difficulties in the design and production processes. To achieve nanoscale size and avoid aggregation during processing or storage, a variety of excipients are utilized.

1. POLYMERIC NANO PARTICLES

• Sodium alginate gelatine polylactic acid
• Polyglycolic acid
• Dextran

2. SOLID LIPID NANO PARTICLES

• Tricaprin
• Tristearin
• Glyceryl monostearate
• Cetyl palmitate
• Palmitic acid.

3. EMULSIONS

• Soybean lecithin
• Egg lecithin
• Polaxamer 188
• Polysorbate 80
• Tyloxapol

4. VESICLE BASED SYSTEMS

• Phosphatidylcholine
• Distearoyl
• Dipalmitoyl phosphatidic acid
• Cholesterol

5. STABILIZERS

• Poly vinyl alcohol
• Poly vinyl pyrrolidone (PVP)
• Polyacrylic acid
• Hydroxypropyl methyl cellulose (HPMC)

Methods of Preparation

1. Phase separation

By continuously swirling the mixture into the polymer-drug solvent phase and then extracting the resultant mixture, the phase separation method causes the polymer to separate into drug-containing droplets. In order to quench these micro-droplets, the droplet is dipped into an insoluble media (both organic and aqueous). The droplet’s hardness and coarsening characteristics are controlled by the amount of time spent soaking in the quenching bath. For later usage, it is gathered by centrifugation, washing, sieving, filtering, and freeze-drying⁶².

2. Nanoprecipitation (solvent displacement/solvent diffusion)

This process shows that the medication and polymer are dissolved in an organic solvent and then moved at a steady pace into an aqueous solution containing surfactants. To fully remove the organic solvent, the resultant colloidal suspension is constantly agitated (800–900 rpm) for 4–5 hours under a fume hood⁶³.

FIGURE.2: Nanoprecipitation Method⁶³

3. Supercritical fluid technology

The use of organic solvents, which are hazardous to both the environment and physiological systems, makes conventional procedures risky. Because a supercritical fluid (SCF) technology solvent stays at a temperature above its critical temperature, when fluid departs as a single phase regardless of pressure, SCF technology has been investigated as a safe and alternative method to create biodegradable micro and nanoparticles. Because it is inexpensive, non-flammable, and harmless, supercritical CO₂ is the most widely utilized SCF. A liquid solvent, like methanol, which is completely miscible with the SCF, is used in the supercritical antisolvent process to dissolve the solute that needs to be micronized. The generation of NPs is caused by the solute's rapid precipitation due to its insolubility non SCF^64,65.

4. Dialysis

A straightforward technique for making PNPs is dialysis. The polymer is dissolved in an organic solvent using this technique. After the solvent loses its solubility, it dislocates inside the membrane, allowing a homogeneous suspension of PNPs to form. Dialysis is carried out through the dialysis membrane against a nonsolvent that was miscible with the prior miscible solvent⁶⁶.

Evaluation of Nanoparticles

1. Surface Charge (Zeta Potential)

The stability, interactions with biological membranes, and cellular uptake of nanoparticles are all influenced by their surface charge, which can be either positive, negative, or neutral. The Zeta potential of a nanoparticle is typically used to determine the particle's surface charge characteristics. This representation of the particles' electrical potential is affected by both the particles' own structure and the medium in which they are distributed. Since the surface charge inhibits particle agglomeration, nanoparticles need to have zeta potentials higher than 30 mV to remain stable in suspension. For best stability, zeta potential values usually fall between -30 and +30 mV. Evaluation Techniques: Electrophoretic light scattering is used to measure zeta potential^67,68.

2. Drug Loading Capacity and Encapsulation Efficiency

The therapeutic impact depends on how much medication can be placed into a nanoparticle and what proportion of the drug is properly encapsulated without deteriorating or being lost during processing. Evaluation techniques include High-Performance Liquid Chromatography (HPLC) and UV-Visible Spectrophotometry⁶⁹.

3. Stability

The shelf-life and efficacy of nanoparticles depend on their physical and chemical stability. Aggregation, medication breakdown, or a reduction in therapeutic action might result from instability. For 90 days, the formulation was stored at 4°C, 1°C, 30°C, and 2°C to test the stability of the produced nanoparticles. The samples were reanalysed after a certain amount of time, such as 0, 1, 2, and 3 months, to determine whether their physical properties, drug content, or drug release rate had changed. Evaluation techniques include freeze-thaw cycling, accelerated stability testing, and storage in various settings^70,71.

4. Immunogenicity

It is important to carefully assess the immune response to the nanoparticles since it may result in unintended side effects or early clearance. Methods of Evaluation: Measurement of cytokine levels, antibody response, and immune cell activity (T-cells, macrophages)⁷².

5. Pharmacokinetics and Biodistribution

The absorption, distribution, metabolism, and excretion (ADME) of the drug-nanoparticle combination are all included in the pharmacokinetic profile. Effective drug delivery depends on dispersion, particularly to the target organ or tissue. Methods of evaluation include blood sample for pharmacokinetic modelling, radiolabelled drug formulations, and in vivo imaging⁷³.

6. Particle Size and Distribution

The capacity of nanoparticles to pass through biological barriers like cell membranes or the blood-brain barrier depends critically on their size. Particles that are smaller (usually between 10 and 200 nm) have better bioavailability and cellular absorption. Photon-correlation spectroscopy, also known as dynamic light scattering, has been demonstrated to be the most reliable and efficient method for determining the sizes of individual particles. Scanning or transmission electron microscopy (SEM or TEM) is frequently used to confirm data generated by photon-correlation spectroscopy. Evaluation techniques include Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), and Dynamic Light Scattering (DLS)^74,75.

7. Drug Content⁷⁶

The amount of medication in the supernatant was then measured using a UV spectrophotometer to create the standard calibration curve. The amount of medication in the supernatant is then subtracted from the total amount needed to create the nanoparticles. The % of drug entrapment as determined by,

% Drug Entrapment = (total drug conc.-total supernatant conc.) /total drug conc. × 100

8. The yield of Nanoparticles⁷⁷

By comparing the total weight of the produced nanoparticles to the total weight of the drug and copolymer combined, the particle yield can be determined.

% Yield = weight of nanoparticle/ weight of polymer and drug fed initially ×100

Applications:

1. Gene Therapy

Gene therapy is the process of replacing a disease-causing broken gene in the DNA with a healthy gene. The gene is usually inserted into the stem cells using a vector. Because stem cells have the ability to self-renew and have a longer lifespan, they are the greatest candidates for gene therapy. Additionally, nanotechnology is essential for delivering genetic materials for gene therapy, including DNA, RNA, and siRNA. Viral vectors, lipid nanoparticles, and dendrimers are examples of nanoparticles that are highly effective at delivering genetic material to target cells. For instance, mRNA-based vaccinations, like the COVID-19 vaccines, use lipid nanoparticles to transfer genetic material into cells⁷⁸.

2. Targeted Drug Delivery

Drug toxicity and adverse effects can be decreased by using nanotechnology to create drug delivery systems that can target particular cells, tissues, or organs. For instance, ligands or antibodies that identify and attach to particular receptors that are overexpressed on the surface of cancer cells can be used to functionalize nanoparticles. This minimizes harm to healthy tissues while enabling direct drug delivery to the tumor⁷⁹.

3. Nanotechnology in the Treatment of Brain Diseases

If the blood-brain barrier (BBB) issue is fixed, brain disease treatments may be successful. Neural tissues and the bloodstream are separated by the blood-brain barrier in the brain. The blood-brain barrier, which keeps the brain's homeostasis intact and stops drugs from accessing the central nervous system (CNS), is the largest barrier to treating brain disorders. Any disturbance of the blood-brain barrier can result in neuro-inflammatory and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and others, but even a damaged blood-brain barrier makes it impossible for drugs to reach the brain. NPs have been used to treat a variety of conditions since the blood-brain barrier was broken down, such as stroke, Parkinson's disease, Alzheimer's disease, and many more that are discussed here. Drug delivery to the brain is made extremely difficult by biological barriers like the blood-brain barrier, which nanoparticles can be engineered to overcome. To increase their permeability through these barriers, nanocarriers such polymeric nanoparticles, liposomes, and solid lipid nanoparticles can be functionalized. For example, targeting ligand-coated nanoparticles, like transferrin, have been created to deliver medications to the brain⁸⁰.

4. Inhalation Therapy

By using nanotechnology to the diagnosis, treatment, and screening of a broad range of diseases, nanomedicine has the potential to fundamentally alter both public and private health. Drugs can be delivered specifically to the lungs through inhalation using nanoparticles. This is especially helpful for conditions including lung cancer, asthma, and chronic obstructive pulmonary disease (COPD). For instance, bronchodilators, corticosteroids, or anticancer medications based on nanoparticles can be inhaled straight into the lungs, improving therapeutic effects and lowering systemic adverse effects⁸¹.

5. Antidiabetic agents

Insulin was combined with a protamine, a cell-penetrating peptide, and then encapsulated in N-trimethyl chitosan chloride-coated mucoadhesive poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The findings indicated that diabetic rats exhibited a quicker onset and a longer-lasting hypoglycemia effect. When compared to subcutaneous insulin injection, the oral delivery system's bioavailability was 17.98 ± 5.61%. It's interesting to note that this oral insulin delivery system has much improved, with greater bioavailability in experimental animals. This suggests that the cells have better internalised the mucoadhesive NPs than native insulin. Thus, conjugating insulin with cell-penetrating peptides and then encasing it in mucoadhesive nanoparticles may be a helpful way to deliver insulin orally⁸².

6. Nanotechnology in Antimicrobial Drug Delivery

The broad-spectrum antibacterial qualities of silver nanoparticles allow them to interfere with cellular processes and damage bacterial cell membranes. Antimicrobial drugs can be delivered more precisely and overcome resistance mechanisms with the help of nanoparticles^83,84.

7. Anticancer agents

Cisplatin is a significant anticancer medication that inhibits DNA synthesis and interferes with cell division through mitosis. The DNA repair mechanism is triggered by damaged DNA. Although cisplatin is a very effective anticancer medication, its full therapeutic potential is restricted because of its toxicity to healthy tissues, which includes nausea, vomiting, and toxicity to the kidneys and ears. Cisplatin's therapeutic index would be improved and medication toxicity would be greatly decreased by tailored delivery to tumor cells⁸⁵.

8. Improved Solubility and Bioavailability

A lot of medications have poor solubility, which reduces their bioavailability. Nanoparticles can improve solubility in a number of ways, such as by increasing surface area and decreasing size⁸⁶.

9. Combination Therapy:

Multiple medications can be co-delivered by nanoparticles, resulting in synergistic effects that improve treatment effectiveness and lower drug resistance. For instance, paclitaxel and cisplatin co-delivered via nanoparticles for increased anti-cancer efficacy⁸⁷.

10. Cosmeceuticals

When employed as vehicles for molecular sunscreens, lipid nanoparticles demonstrated a synergistic impact of UV scattering. Benefits from these insights include the ability to lower the molecular sunscreen's concentration and, thus, any potential negative effects, as well as the expenses associated with creating pricey sunscreens. Furthermore, it may be possible to create sunscreen solutions with lower and medium UV protection levels by using lipid nanoparticles. The miscibility of the active ingredient in the lipid used to produce the lipid nanoparticles is the primary determinant of their loading capacity. The German business Dr. Rimpler GmbH, located in Wedemark/Hannover, released the first two cosmetics utilizing nanostructured lipid carrier technology. The success of lipid nanoparticles in the antiaging sector was demonstrated in October 2005 when the products NanoRepair Q10 cream and NanoRepair Q10 serum (Dr. Kurt Richter Laboratorien GmbH, Berlin, Germany) were released onto the cosmetic market⁸⁸.

Table 2: Examples Of Marketed formulations of nanoparticles^89-91

Recent Research

Nanotechnology research has risen significantly over the last few decades, and the healthcare industry has also drawn more interest. Technological developments have enhanced our comprehension of some of the complex etiologists involved and increased the likelihood of early diagnosis and possible therapeutic uses of nanomedicine. Numerous Nano Systems have proven to be successful in reducing barriers in a number of healthcare fields, despite the fact that they have only been partially employed and integrated. Although the development of nanomedicines and nanodevices is still in its infancy, one tactic to hasten this process is to concentrate research efforts on developing innovative solutions to overcome the related challenges. The constant development of nanotechnology-based methods has sparked optimism that crippling and potentially fatal diseases may soon be effectively treated. Closing the gaps caused by inadequate efficacy and preclinical safety studies must be our top priority if we are to quickly and completely realize the vast potential of nanotechnology, which is now unrealized. While there are many problems that nanotechnology can solve, this does not mean that there are not any challenges or limitations. Recent developments in medication delivery using nanotechnology have completely changed how many diseases are treated, especially those related to infectious diseases, neurological diseases, and cancer. By enabling regulated release profiles, improved bioavailability, and targeted medication administration, nanotechnology reduces side effects and boosts therapeutic efficacy. Drug Delivery Systems Based on Nanoparticles: Nanoparticles can effectively transport medications to certain bodily locations due to their special physicochemical characteristics, such as a high surface area-to-volume ratio⁹².The capacity of nanotechnology to target medications to particular cells or tissues is one of its primary benefits. This is frequently accomplished by adding targeting ligands, including peptides, antibodies, or small molecules, to the surface of nanoparticles. These ligands bind selectively to receptors that are overexpressed on disease cells⁹³.

Conclusion

With notable advancements in targeting, bioavailability, and therapeutic results, nanotechnology is pushing the limits of medication delivery. The goal of current research is to overcome the obstacles of toxicity, scalability, and stability. Nanomedicines have the ability to treat a wide range of complicated illnesses as new technologies are developed, which bodes well for future treatments that are more individualized and efficient. By improving the functionality and efficiency of commonplace items, nanotechnology is simplifying our daily lives. By supplying cleaner, renewable energy and healthier air and water, it helps to maintain environmental purity for a longer-lasting future than would otherwise be possible. In direct response to the increasing interest in nanotechnology, top institutions, businesses, and organizations are increasing their investment in research and development. This area of science is at the forefront right now because of the substantial research being done to put nanotechnology into practice. It is now being evaluated for a number of innovative uses with the goal of improving the product or process's performance and efficiency, which would lower the cost and make it more affordable for a larger market. Nanotechnology has an exciting and promising future due to its effectiveness and minimal environmental impact. Nowadays, drugs are successfully delivered via nanoparticles. Nanoparticles, one of the most important tools in nanomedicine, offer significant benefits in drug transport and targeting, as well as the potential for combined therapy and diagnostics. Technically, the following tactics are difficult to implement: Technologies under investigation include viral-like systems for intracellular systems, biomimetic polymer architecture, systems that interact with my body smartly, nanochips for NPs release, carriers for advanced polymers for peptide/protein delivery, and control of sensitive drugs. Drug delivery systems were developed to control the quantity and pace of drug administration or to disperse pharmaceuticals. Most significant and well-established internal drug delivery research projects use formulations and dispersions that contain components as small as nanometers. This work built a nanoparticle data storage system after analyzing the earlier studies. By classifying them, going over the various ways to make them, and going over their numerous uses, this page provides an overview of nanoparticles. Our study's results indicate that throughout the previous several years, the prevalence of nanoparticles has rapidly increased. The costs of some of the produced nanoparticles are competitive, and there are several opportunities or potential projects that might be done. For example, the production of nanoparticles from plant materials has become more and more popular recently because it is both cost-effective and environmentally friendly⁹⁴.

Acknowledgement: None

Conflicts of Interests: There are no conflicts of interest.

Funding: Nil

Authors Contributions: All the authors have contributed equally.

Source of Support: Nil

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Ethics approval: Not Applicable.

References:

1. Sahu T, Ratre RK, Chauhan S, Lvks Bhaskar, et al., Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science, Journal of Drug Delivery Science and Technology, 2021; 63:1773-2247. https://doi.org/10.1016/j.jddst.2021.102487
2. Medical Advisory Secretariat. Coil embolization for intracranial aneurysms: an evidence-based analysis, Ont Health Technol Assess Ser, 2006; 6(1):111-114.
3. Sichert JA, Tong Y, Mutz N, Vollmer M, et al., Quantum Size Effect in Organometal Halide Perovskite Nanoplatelets, Nano Lett, 2015; 15(10):6521-6527. https://doi.org/10.1021/acs.nanolett.5b02985 PMid:26327242
4. Zandonella C, The tiny toolkit, Nature, 2003; 423: 10-12. https://doi.org/10.1038/423010a PMid:12721596
5. Moghimi SM, Farhangrazi ZS, Nanomedicine and the complement paradigm, Nanomedicine: Nanotechnology, Biology and Medicine, 2013; 9(4):458-460. https://doi.org/10.1016/j.nano.2013.02.011 PMid:23499667
6. Zarrintaj P, Moghaddam AS, Manouchehri S, Atoufi Z, et al., Can regenerative medicine and nanotechnology combine to heal wounds The search for the ideal wound dressing, Nanomedicine, 2017; 12(19):2403-2422. https://doi.org/10.2217/nnm-2017-0173 PMid:28868968
7. Stirland DL, Nichols JW, Denison TA, Bae YH, Targeted drug delivery for cancer therapy, Biomaterials for Cancer Therapeutics, Woodhead Publishing, 2013; 31-56. https://doi.org/10.1533/9780857096760.1.31
8. Dobrovolskaia MA, Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy, Journal of Control Release, 2015; 571-83. https://doi.org/10.1016/j.jconrel.2015.08.056 PMid:26348388 PMCid:PMC4688153
9. Farokhzad OC, Langer R, Impact of nanotechnology on drug delivery, ACS Nano, 2009; 3(1):16-20. https://doi.org/10.1021/nn900002m PMid:19206243
10. Reibold M, Paufler P, Levin A et al., Carbon nanotubes in an ancient Damascus sabre, Nature, 2006; 444(7117): 286. https://doi.org/10.1038/444286a PMid:17108950
11. Mappes T, Jahr N, Csaki A, et al., The invention of immersion ultramicroscopy in 1912-the birth of nanotechnology, Angew Chem Int Ed Engl, 2012; 51(45):11208-11212. https://doi.org/10.1002/anie.201204688 PMid:23065955
12. Krukemeyer MG, Krenn V, Huebner F, Wagner W et al., History and Possible Uses of Nanomedicine Based on Nanoparticles and Nanotechnological Progress, Journal of Nanomedicine & Nanotechnology, 2015; 6: 336. https://doi.org/10.4172/2157-7439.1000336
13. Feynman RP, There's plenty of room at the bottom, An invitation to enter a new field of physics, Engineering and Science (Caltech), 1960; 23: 22-36.
14. Drexler KE, Engines of Creation, The coming era of nanotechnology, Anchor Books, New York, 1986.
15. Drexler KE, Peterson C, Pergamit G, Unbounding the Future: The nanotechnology revolution, Morrow, New York, 1991.
16. Freitas Jr RA, Nanomedicine, vol. I: Basic capabilities, Landes Bioscience, Georgetown, TX, USA, 1999.
17. Kreuter J, Nanoparticles a historical perspective, International Journal of Pharmaceutics, 2007; 331(1):1-10. https://doi.org/10.1016/j.ijpharm.2006.10.021 PMid:17110063
18. Noorlander CW, Kooi MW, Oomen AG, Park MV, et al., Horizon scan of nanomedicinal products, Nanomedicine, 2015; 10(10):1599-1608. https://doi.org/10.2217/nnm.15.21 PMid:25694061
19. Agrawal M, Saraf S, Antimisiaris SG, Hamano N, et al., Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region, Expert Opinion on Drug Delivery, 2018; 15(6):589-617. https://doi.org/10.1080/17425247.2018.1471058 PMid:29733231
20. Jogani VV, Shah PJ, Mishra P, Mishra AK, et al., Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting, Alzheimer Disease and Association Disorder, 2008; 22(2):116-24. https://doi.org/10.1097/WAD.0b013e318157205b .
21. Majumder J, Taratula O, Minko T, Nanocarrier-based systems for targeted and site specific therapeutic delivery, Advanced Drug Delivery Reviews, 2019; 144:57-77. https://doi.org/10.1016/j.addr.2019.07.010 PMid:31400350 PMCid:PMC6748653
22. Li X, Tsibouklis J, Weng T, et al., Nano carriers for drug transport across the blood-brain barrier, Journal of Drug Target, 2017; 25(1):17-28. https://doi.org/10.1080/1061186X.2016.1184272 PMid:27126681
23. Agrawal M, Saraf S, Antimisiaris SG, Hamano N, et al., Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region, Expert Opinion on Drug Delivery, 2018; 15(6):589-617. https://doi.org/10.1080/17425247.2018.1471058 PMid:29733231
24. Talelli M, Hennink WE, Thermosensitive polymeric micelles for targeted drug delivery, Nanomedicine, 2011; 6(7):1245-55. https://doi.org/10.2217/nnm.11.91 PMid:21929459
25. Shah P, Chavda K, Vyas B, Patel S, Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: Role of P-gp inhibition, Drug Delivery Translational Research, 2021; 11: 1166-1185. https://doi.org/10.1007/s13346-020-00839-9 PMid:32804301
26. Miller MR, Shaw CA, Langrish JP, From particles to patients: oxidative stress and the cardiovascular effects of air pollution, Future Cardiol, 2012; 8(4):577-602. https://doi.org/10.2217/fca.12.43 PMid:22871197
27. Alexis F, Pridgen E, Molnar LK, Farokhzad OC, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol Pharm, 2008; 5(4):505-15. https://doi.org/10.1021/mp800051m PMid:18672949 PMCid:PMC2663893
28. Prabhu RH, Patravale VB, Joshi MD, Polymeric nanoparticles for targeted treatment in oncology: current insights, International Journal of Nanomedicine, 2015; 10:1001-1018. https://doi.org/10.2147/IJN.S56932 PMid:25678788 PMCid:PMC4324541
29. Danhier F, Lecouturier N, Vroman B, Jérôme C, et al., Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation, Journal of Controlled Release, 2009; 133(1):11-7. https://doi.org/10.1016/j.jconrel.2008.09.086 PMid:18950666
30. Oerlemans C, Bult W, Bos M, Storm G, et al., Polymeric micelles in anticancer therapy: targeting, imaging and triggered release, Pharmaceutical Research, 2010; 27(12):2569-2589. https://doi.org/10.1007/s11095-010-0233-4 PMid:20725771 PMCid:PMC2982955
31. Jin X, Mo R, Ding Y, Zheng W, et al., Paclitaxel-loaded N-octyl-O-sulphate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance, Molecular Pharmaceutic Journal, 2014; 11(1):145-157. https://doi.org/10.1021/mp400340k PMid:24261922
32. Bharali DJ, Khalil M, Gurbuz M, Simone TM, et al., Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers, International Journal of Nanomedicine, 2009; 4:1-7.
33. Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, et al., Dendritic molecular capsules for hydrophobic compounds, Journal of American Chemical Society, 2003; 125(50):15485-15489. https://doi.org/10.1021/ja0347383 PMid:14664594
34. Levine DH, Ghoroghchian PP, Freudenberg J, Zhang G, et al., Polymersomes: a new multi-functional tool for cancer diagnosis and therapy, Methods, 2008; 46(1):25-32. https://doi.org/10.1016/j.ymeth.2008.05.006 PMid:18572025 PMCid:PMC2714227
35. Han L, Tang C, Yin C, Effect of binding affinity for siRNA on the in vivo antitumor efficacy of polyplexes, Biomaterials, 2013; 34(21):5317-5327. https://doi.org/10.1016/j.biomaterials.2013.03.060 PMid:23591392
36. Wong HL, Rauth AM, Bendayan R, Manias JL, et al., A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells, Pharmaceutical Research, 2006; 23(7):1574-1585. https://doi.org/10.1007/s11095-006-0282-x PMid:16786442
37. Asati A, Santra S, Kaittanis C, Perez JM, Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles, ACS Nano, 2010; 4(9):5321–5331. doi: 10.1021/nn100816s
38. Couvreur P, Vauthier C, Nanotechnology: intelligent design to treat complex disease, Pharmaceutical Research, 2006; 23(7):1417-1450. https://doi.org/10.1007/s11095-006-0284-8 PMid:16779701
39. Peppas NA, Bures P, Leobandung W, Ichikawa H, Hydrogels in pharmaceutical formulations, European Journal of Pharmaceutical and Biopharmaceutics, 2000; 50(1):27-46. https://doi.org/10.1016/S0939-6411(00)00090-4 PMid:10840191
40. De Jong WH, Borm PJ, Drug delivery and nanoparticles: applications and hazards, International Journal of Nanomedicine, 2008; 3(2):133-149. https://doi.org/10.2147/IJN.S596 PMid:18686775 PMCid:PMC2527668
41. Dufresne MH, Miele E, The impact of nanoparticles on drug delivery, Nanomedicine: Nanotechnology, Biology and Medicine, 2015; 11(7):1679-1694.
42. Maeda H, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Advances Enzyme Regulation, 2001; 41:189-207. https://doi.org/10.1016/S0065-2571(00)00013-3 PMid:11384745
43. Kroll, Jesse H. et al. "Carbon Oxidation State as a Metric for Describing the Chemistry of Atmospheric Organic Aerosol." Nature Chemistry 3.2 (2011); 133-139. https://doi.org/10.1038/nchem.948 PMid:21258386
44. Peres M, Pereira JA, "Nanomedicine: Advances in Nanotechnology for Drug Delivery", Pharmaceuticals, 2022; 15(4):453.
45. Jain RK, et al., "Delivery of nanomedicines: role of nanoparticle size and shape." Molecular Pharmaceutics, 2006; 3(5):656-660
46. Elsabahy M, Wooley KL, Design of polymeric nanoparticles for biomedical delivery applications, Chemical Society Reviews, 2012; 41:2545-2561. https://doi.org/10.1039/c2cs15327k PMid:22334259 PMCid:PMC3299918
47. Guo S, Li D, Zhang L, Li J, et al., Monodisperse mesoporous superparamagnetic single-crystal magnetite nanoparticles for drug delivery, Biomaterials, 2009; 30(10):1881-1889. https://doi.org/10.1016/j.biomaterials.2008.12.042 .
48. Calvo P, Vila-Jato JL, Alonso MJ, Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers, Journal of Pharmaceutical Sciences, 1996; 85(5):530-6. https://doi.org/10.1021/js950474+ PMid:8742946
49. Moorthi C, Kathiresan, Fabrication of Dual Drug Loaded Polymeric Nanosuspension: Incorporating Analytical Hierarchy Process and Data Envelopment Analysis in the Selection of a Suitable Method, International Journal of Pharmacy and Pharmaceutical Science, 2013; 5(2):499-504. https://api.semanticscholar.org/CorpusID:73612613
50. Morose G, The 5 principles of design for safer nanotechnology, Journal of Cleaner Production, 2010; 18(3):285-289. https://doi.org/10.1016/j.jclepro.2009.10.001
51. Marin E, Briceño ML, Caballero GC, Critical evaluation of biodegradable polymers used in nanodrugs, International Journal of Nanomedicines, 2013; 8:3071. https://doi.org/10.1016/j.jclepro.2009.10.001
52. Herrero EP, Alonso MJ, Csaba N, Polymer-based oral peptide nanomedicines, Therapeutic Delivery, 2012; 3(5):657-668. https://doi.org/10.4155/tde.12.40 PMid:22834409
53. Kadajji VG, Betageri GV, Water Soluble Polymers for Pharmaceutical Applications, Polymers, 2011; 3(4):1972-2009. https://doi.org/10.3390/polym3041972
54. Kalepu S, Manthina M, Padavala V, Oral lipid-based drug delivery systems-an overview, Acta Pharmaceutica Sinica B 3, 2013; 361-372. https://doi.org/10.1016/j.apsb.2013.10.001
55. Cavalli R, Caputo O, Carlotti ME, Trotta M, et al., Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, International Journal of Pharmaceutics, 1997; 148:47-54. https://doi.org/10.1016/S0378-5173(96)04822-3
56. Mehta SK, Jindal N, Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs, Colloids Surfaces B:Biointerfaces, 2013; 101:434-441. https://doi.org/10.1016/j.colsurfb.2012.07.006 PMid:23010052
57. Singh P, Prabakaran D, Jain S, Mishra V, et al., Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization, International Journal of Pharmaceutics, 2004; 278(2):379-390. https://doi.org/10.1016/j.ijpharm.2004.03.014 PMid:15196642
58. Shukla A, Khatri K, Gupta PN, Goyal AK, et al., Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes), Journal of Pharmacy and Pharmaceutical Sciences, 2008; 11(1):59-66. https://doi.org/10.18433/J3K01M PMid:18445364
59. Venkateswarlu V, Manjunath K, Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles, Journal of Controlled Release, 2004; 95(3):627-638. https://doi.org/10.1016/j.jconrel.2004.01.005 PMid:15023472
60. Yang S, Zhu J, Lu Y, Liang B, et al., Body distribution of camptothecin solid lipid nanoparticles after oral administration, Pharmaceutical Research, 1999; 16(5):751-757. https://doi.org/10.1023/A:1018888927852 PMid:10350020
61. Hu L, Xing Q, Meng J, Shang C, Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles, AAPS PharmSciTech, 2010; 11(2):582-587. https://doi.org/10.1208/s12249-010-9410-3 PMid:20352534 PMCid:PMC2902353
62. Makadia HK, Siegel SJ, Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier, Polymers (Basel), 2011; 3(3):1377-1397. https://doi.org/10.3390/polym3031377 PMid:22577513 PMCid:PMC3347861
63. Ali H, Kalashnikova I, White MA, Sherman M, et al., Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model, International Journal of Pharmaceutics, 2013; 454(1):149-157. https://doi.org/10.1016/j.ijpharm.2013.07.010 PMid:23850397 PMCid:PMC3800161
64. Chernyak Y, Henon F, Harris RB, Gould RD, et al., Formation of perfluoropolyether coatings by the rapid expansion of supercritical solutions (RESS) process Part 1: experimental results, Industrial & Engineering Chemistry Research journal 2001; 40(26):6118-6126. https://doi.org/10.1021/ie010267m
65. Desai MP, Labhasetwar V, Walter E, et al., The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent, Pharmaceutical Research 14, 1997; 1568-1573 https://doi.org/10.1023/A:1012126301290 PMid:9434276
66. Rao JP, Geckeler KE, Polymer nanoparticles: preparation techniques and size-control Parameters, Progress in Polymer Science, 2011; 36(7):887-913. https://doi.org/10.1016/j.progpolymsci.2011.01.001
67. Öztürk K, Kaplan M, Çalış S. Effects of nanoparticle size, shape, and zeta potential on drug delivery, International Journal of Pharmaceutics, 2024;666. https://doi.org/10.1016/j.ijpharm.2024.124799 PMid:39369767
68. Couvreur P, Barratt G, Fattal E, Legrand P, et al., Nanocapsule technology: a review. Critical Reviews in Therapeutic Drug Carrier Systems, 2002; 19(2):99-134. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v19.i2.10 PMid:12197610
69. Li X, et al., Nanoparticle-based Drug Delivery Systems for Targeted Cancer Therapy, Nanomedicine: Nanotech Bio and Medi, 2015; 11(6):1211-1233. https://doi.org/10.1016/j.smaim.2020.04.001 PMid:34553138 PMCid:PMC8455119
70. Sahana D., et al., Stability of Nanoparticles in Drug Delivery, Current Drug Metabolism, 2019; 20(6):492-506.
71. Muthu MS, Feng SS, Pharmaceutical stability aspects of nanomedicines, Nanomedicine, 2009; 4(8):857-60. https://doi.org/10.2217/nnm.09.75 PMid:19958220
72. Liu Y, et al., Immunogenicity of Nanoparticles, Nature Materials, 2017; 16(4):344-357.
73. Ferrari M., Cancer Nanotechnology: Opportunities and Challenges, Nature Reviews Cancer, 2005; 5(3):161-171. https://doi.org/10.1038/nrc1566 PMid:15738981
74. Kallinteri P, et al., Nanoparticles in Drug Delivery Systems, Nanomedi: Nanotech Biology and Medicine, 2015; 11(5):1115-1134.
75. Jin Y, Huan Y, Zhao JX, Wu M, Kannan S, Toxicity of nanomaterials to living cells, Proc Natl Acad Sci U S A, 2005; 59:42-43.
76. Mohanraj VJ, Chen Y, Nanoparticles-a review, J. Pharm. Res, 2006; 5(1):561-573. https://doi.org/10.4314/tjpr.v5i1.14634
77. Tsolou A, Angelou E, Didaskalou S, Bikiaris D, et al., Folate and Pegylated Aliphatic Polyester Nanoparticles for Targeted Anticancer Drug Delivery, Intern J of Nano, 2020; 15:4899-4918. https://doi.org/10.2147/IJN.S244712 PMid:32764924 PMCid:PMC7369311
78. Witzigmann D, Woodrow K, Lipid nanoparticles for RNA delivery, Current Opinion in Solid State and Materials Science, 2017; 21(1):1-9.
79. Langer R, Tirrell DA, Designing materials for biology and medicine, Nature, 2004; 428(6982):487-492. https://doi.org/10.1038/nature02388 PMid:15057821
80. Patel MM, Patel VH, Nanoparticles in drug delivery systems for treatment of central nervous system disorders, Current Drug Delivery, 2015; 12(1):1-11.
81. Dhanik A, Gupta R, Nanoparticles in inhalation drug delivery, J of Drug Del Sci and Technol, 2020; 56:101549. https://doi.org/10.1016/j.jddst.2020.101549
82. Sheng J, He H, Han L, Qin J, et al., Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates, J Contr Rel 2016; 233:181-190. https://doi.org/10.1016/j.jconrel.2016.05.015 PMid:27178809
83. Fong J, Liu Y, Nanotechnology in antimicrobial therapy: A review, J of Antimicro Chemo, 2018; 73(9):2355-2367.
84. Sondi I, Salopek-Sondi B, Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria, J of Colloid and Interface Sci, 2004; 275(1):177-182. https://doi.org/10.1016/j.jcis.2004.02.012 PMid:15158396
85. Rosenberg B, Fundamental studies with cisplatin, Cancer, 1985; 55(10):2303-23l6. https://doi.org/10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L PMid:3886121
86. Jain KK, Nanobiotechnology: a convergence of nanotechnology and biotechnology, Nature Nanotechnology, 2008; 3(4):201-204.
87. Sethi JK, et al., Nanoparticle-mediated Combination Therapy: A Novel Approach to Cancer Treatment, Frontiers in Pharmacology, 2019; 10:786.
88. Muller RH, Petersen RD, Hommoss A, Pardeike J, Nanostructured lipid carriers (NLC) in cosmetic dermal products, Adv. Drug Deliv. Rev., 2007; 59:522-530. https://doi.org/10.1016/j.addr.2007.04.012 PMid:17602783
89. Barenholz Y, Doxil®-Liposomal formulations of doxorubicin: A review, J of Controlled Release, 2012; 160(2):117-134. https://doi.org/10.1016/j.jconrel.2012.03.020 PMid:22484195
90. Desai N, Nanoparticle albumin-bound paclitaxel (Abraxane®): A novel injectable formulation of paclitaxel, Cancer Chemotherapy and Pharmacology, 2012; 62(5):151-160. https://doi.org/10.1007/978-981-10-2116-9_6
91. Gordeuk VR, et al., Ferumoxytol in iron-deficiency anaemia, The New England J of Medi, 2009; 361(4):314-324.
92. Raza K, et al., Recent developments in nanocarrier-based drug delivery for cancer therapy. Nanomedicine: Nanotech, Bio and Medi, 2023; 42(4):163-178.
93. Zhao L, et al., Targeted drug delivery via nanoparticle systems: Opportunities and challenges, Frontiers in Pharmacology, 2022; 13:803186.
94. Lachman L, Liberman HA, Kaing JL, Theory and practice of Industrial Pharmacy, 3rd ed. Mumbai: Varghese Publishing House; 1987. P. 26-30